Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma
Personalized medicine aims to tailor treatment to patients based on their individual genetic or molecular background. Especially in diseases with a large molecular heterogeneity, such as diffuse large B-cell lymphoma (DLBCL), personalized medicine has the potential to improve outcome and/or to reduc...
Guardado en:
Autores principales: | Kirsten Thobe, Fabian Konrath, Björn Chapuy, Jana Wolf |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fa11e8ee04db491da78735748c189709 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma
por: Kristin Stirm, et al.
Publicado: (2021) -
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
por: Falgàs A, et al.
Publicado: (2021) -
Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
por: Liping Fan, et al.
Publicado: (2021) -
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
por: Dipenkumar Modi, et al.
Publicado: (2021) -
Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Edit Porpaczy, et al.
Publicado: (2021)